Nyxoah SA
NYXH
$2.95
$0.020.68%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
4/30/2026
-
Zacks Investment Research
4/30/2026
-
Zacks Investment Research
4/29/2026
-
Tickeron - Stocks
4/28/2026
-
Globe Newswire
4/19/2026
-
TipRanks Financial Blog
4/18/2026
-
Tickeron - Stocks
4/11/2026
-
TipRanks Financial Blog
4/11/2026
-
TipRanks Financial Blog
4/10/2026
-
MarketBeat
4/10/2026
-
TipRanks Financial Blog
4/9/2026
-
Tickeron - Technical Analysis
4/4/2026
-
Yahoo! Finance: News
4/4/2026
-
Insider Monkey
4/4/2026
-
TipRanks Financial Blog
4/3/2026
-
Insider Monkey
4/2/2026
-
TipRanks Financial Blog
4/2/2026
-
TipRanks Financial Blog
3/30/2026
-
MarketBeat
3/28/2026
-
TipRanks Financial Blog
3/27/2026
-
Tickeron - Technical Analysis
3/24/2026
-
Tickeron - Technical Analysis
3/23/2026
-
MarketBeat
3/23/2026
-
TipRanks Financial Blog
3/23/2026
-
TipRanks Financial Blog
3/23/2026
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, March 26, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
32 1 045 90 75
Address
Rue Edouard Belin 12
Mont-Saint-Guibert, 1435
Mont-Saint-Guibert, 1435
Country
Year Founded
Business Description
Sector
Industry
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal...
more